John Patience Biography and Net Worth

Chairman of Biodesix

John Patience has served as a Director of the Company since June 2008 and Chairman of the Board since September 2020. Mr. Patience currently serves as both a Director and Chairman of the board of Accelerate Diagnostics, Inc. (NASDAQ: AXDX) and has served in that capacity since joining the board in 2012. Mr. Patience served as a director of Ventana Medical Systems, Inc. from 1989 and as Vice Chairman from 1999 until Ventana’s acquisition by Roche in 2008. Mr. Patience also served as a director of Stericycle, Inc. (NASDAQ: SRCL) since its founding in 1989 to June 2018. Mr. Patience is also a founding partner of Crabtree Partners, a private equity investment partnership in Lake Forest, Illinois. Mr. Patience was previously a partner of a venture capital investment firm that provided both Ventana and Stericycle with early stage funding. Mr. Patience was also previously a partner at the consulting firm McKinsey & Co., Inc., specializing in health care. Mr. Patience holds a B.A. in Liberal Arts and an L.L.B. from the University of Sydney, Australia, and an M.B.A. from the University of Pennsylvania’s Wharton School of Business.

What is John Patience's net worth?: The estimated net worth of John Patience is at least $5.92 million as of November 21st, 2022. Mr. Patience owns 4,550,483 shares of Biodesix stock worth more than $5,915,628 as of November 2nd. This net worth evaluation does not reflect any other assets that Mr. Patience may own. Learn More about John Patience's net worth.
How do I contact John Patience?: The corporate mailing address for Mr. Patience and other Biodesix executives is , , . Biodesix can also be reached via phone at 303-417-0500 and via email at [email protected]. Learn More on John Patience's contact information.
Has John Patience been buying or selling shares of Biodesix?: John Patience has not been actively trading shares of Biodesix over the course of the past ninety days. Most recently, on Monday, November 21st, John Patience bought 1,739,130 shares of Biodesix stock. The stock was acquired at an average cost of $1.15 per share, with a total value of $1,999,999.50. Following the completion of the transaction, the chairman now directly owns 4,550,483 shares of the company's stock, valued at $5,233,055.45. Learn More on John Patience's trading history.
Who are Biodesix's active insiders?: Biodesix's insider roster includes Robin Cowie (CFO), Scott Hutton (CEO), John Patience (Chairman), Jack Schuler (Director), and Charles Watts (Director). Learn More on Biodesix's active insiders.
Are insiders buying or selling shares of Biodesix?: During the last twelve months, insiders at the sold shares 24 times. They sold a total of 109,606 shares worth more than $193,017.28. The most recent insider tranaction occured on August, 12th when CAO Chris Vazquez sold 54 shares worth more than $84.78. Insiders at Biodesix own 69.2% of the company. Learn More about insider trades at Biodesix.
Information on this page was last updated on 8/12/2024.

John Patience Insider Trading History at Biodesix

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
11/21/2022	Buy	1,739,130	$1.15	$1,999,999.50	4,550,483
4/7/2022	Buy	279,329	$1.79	$499,998.91	337,926
11/18/2021	Buy	9,497	$6.34	$60,210.98
8/19/2021	Buy	8,396	$8.04	$67,503.84
8/17/2021	Buy	1,604	$7.12	$11,420.48	58,597

John Patience Buying and Selling Activity at Biodesix

Biodesix Company Overview

Biodesix, Inc. operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules. It also provides GeneStrat ddPCR and NGS, and VeriStrat tests, which are used in the diagnosis of lung cancer to measure the presence of mutations in the tumor and the state of the patient's immune system to establish the patient's prognosis and help guide treatment decisions. In addition, the company, through its partnership with Bio-Rad Laboratories, Inc., provides Bio-Rad SARS-CoV-2 ddPCR, a COVID-19 Test under Biodesix WorkSafe testing program; and Platelia SARS-CoV-2 Total Ab test, an antibody test for detecting a B-cell immune response to SARS-CoV-2 that indicate recent or prior infection. Further, it offers diagnostic and clinical research, as well as clinical trial testing services to biopharmaceutical companies; and discovers, develops, and commercializes companion diagnostics. The company was formerly known as Elston Technologies, Inc. and as changed to Biodesix, Inc. in 2006. Biodesix, Inc. was incorporated in 2005 and is headquartered in Louisville, Colorado.

Today's Range

Now: $1.30

$1.28

$1.67

50 Day Range

MA: $1.72

$1.30

$1.96

2 Week Range

Now: $1.30

$1.15

$2.21

Volume

554,657 shs

Average Volume

149,748 shs

Market Capitalization

$188.73 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.22

Watch this before it gets removed

From Porter & Company | Ad

If you missed it, my emergency election broadcast is now available - but will be removed soon

Click here to watch it now.